<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007591</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 80190-O25</org_study_id>
    <nct_id>NCT01007591</nct_id>
  </id_info>
  <brief_title>A Study Comparing LEO 80190 Ointment With Hydrocortisone Ointment, Both Applied Once Daily in the Treatment of Psoriasis Vulgaris on the Face and Intertriginous Areas</brief_title>
  <official_title>Calcipotriol Plus Hydrocortisone in Paediatric Patients (Aged 6 to 17 Years) With Psoriasis Vulgaris on the Face and on the Intertriginous Areas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An international, multi-centre, prospective, randomised, double-blind, active-controlled,
      2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17
      years) with psoriasis vulgaris on the face and on the intertriginous areas
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage Change in Psoriasis Area and Severity Index (PASI) of the Face Last Observation Carried Forward (LOCF) at End of Treatment</measure>
    <time_frame>From baseline (Day 0) to end of treatment (Week 8)</time_frame>
    <description>PASI of the face was to be calculated based on the (sub)investigator's assessment of extent (E), redness (R), thickness (T) and scaliness (S) using the following formula:
0.05 (R+T+S) E
It ranged from 0 to 3.6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment (IGA) of Disease Severity on the Face LOCF</measure>
    <time_frame>At end of treatment (Week 8)</time_frame>
    <description>For subjects with a baseline (Day 0) severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of the face.
For subjects with a baseline (Day 0) severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of the face.
At baseline (Day 0) to end of treatment (Week 8) the (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below.
Clear, almost clear, mild, moderate, severe and very severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change in PASI of the Face LOCF at Week 4</measure>
    <time_frame>From baseline (Day 0) to Week 4 (Day 28)</time_frame>
    <description>PASI of the face was to be calculated based on the (sub)investigator's assessment of extent (E), redness (R), thickness (T) and scaliness (S) using the following formula:
0.05 (R+T+S) E It ranged from 0 to 3.6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment (IGA) of Disease Severity of the Intertriginous Areas LOCF</measure>
    <time_frame>At end of treatment (Week 8)</time_frame>
    <description>At baseline (Day 0) to end of treatment (Week 8) the (sub)investigator made an assessment of the disease severity of the intertriginous areas using the following 6-category scale.
Clear, almost clear, mild, moderate, severe and very severe.
For subjects with a baseline (Day 0) severity of moderate or worse - &quot;controlled disease&quot; of the intertriginous areas was defined as clear or almost clear according to the IGA of the intertriginous areas.
For subjects with a baseline (Day 0) severity of mild - &quot;controlled disease&quot; of the intertriginous areas was defined as clear according to the IGA of the intertriginous areas.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Percentage Change in Total Sign Score (TSS) of the Intertriginous Areas LOCF</measure>
    <time_frame>From baseline (Day 0) to end of treatment (Week 8)</time_frame>
    <description>For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the intertriginous areas was determined according to the scale below:
Redness 0.none
mild
moderate
severe
very severe
Thickness
0.none
mild
moderate
severe
very severe
Scaliness
0.none
mild
moderate
severe
very severe A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS ranging from 0 to 12.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>LEO 80190 ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydrocortisone 10 mg/g ointment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 80190</intervention_name>
    <description>Applied once daily</description>
    <arm_group_label>LEO 80190 ointment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone</intervention_name>
    <description>Applied once daily</description>
    <arm_group_label>Hydrocortisone 10 mg/g ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of psoriasis vulgaris involving the face

          -  Clinical signs of psoriasis vulgaris on the trunk and/or on the limbs, or earlier
             diagnosed with psoriasis vulgaris on the trunk and/or limbs. The extent and severity
             of psoriasis vulgaris on trunk and/or limbs should be amenable to topical therapy with
             any of the allowed medications

          -  An extent of psoriatic involvement of the face of at least 5 cm2 (the sum of all
             facial lesions)

          -  Treatment areas (the face and the intertriginous areas) amenable to topical treatment
             with a maximum of 30 g (6 to 11 years) or 45 g (12 to 17 years) of ointment per week

          -  Disease severity graded as mild, moderate or severe according to the investigator's
             global assessment of disease severity of the face

          -  Aged 6 to 17 years

        Exclusion Criteria:

          -  Systemic treatment with therapies other than biologicals with a potential effect on
             psoriasis vulgaris within the 4-week period prior to randomisation

          -  Systemic treatment with biological therapies (marketed or not marketed) with a
             possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months
             (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives
             (which-ever is longer) for experimental biological products prior to randomisation

          -  PUVA therapy or Grenz ray therapy within the 4-week period prior to randomisation

          -  UVB therapy within the 2-week period prior to randomisation

          -  Topical treatment of psoriasis vulgaris lesions on the face or on the intertriginous
             areas within the 2-week period prior to randomisation

          -  Topical treatment with very potent WHO group IV corticosteroids within the 2-week
             period prior to randomisation

          -  Initiation of or expected changes to concomitant medication that may affect psoriasis
             vulgaris (e.g., beta blockers, anti-malaria drugs, lithium and ACE inhibitors) during
             the treatment phase of the study

          -  Current diagnosis of erythrodermic, exfoliative or pustular psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frédéric Cambazard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FRANCE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Saint-Etienne Hôpital NOrd</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>November 3, 2009</study_first_submitted>
  <study_first_submitted_qc>November 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2009</study_first_posted>
  <results_first_submitted>March 23, 2018</results_first_submitted>
  <results_first_submitted_qc>January 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 15, 2019</results_first_posted>
  <last_update_submitted>January 4, 2019</last_update_submitted>
  <last_update_submitted_qc>January 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>LEO 80190 Ointment</title>
          <description>LEO 80190: Applied once daily</description>
        </group>
        <group group_id="P2">
          <title>Hydrocortisone 10 mg/g Ointment</title>
          <description>Hydrocortisone: Applied once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>LEO 80190 Ointment</title>
          <description>LEO 80190: Applied once daily</description>
        </group>
        <group group_id="B2">
          <title>Hydrocortisone 10 mg/g Ointment</title>
          <description>Hydrocortisone: Applied once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Years</title>
              <category_list>
                <category>
                  <title>6-8</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9-11</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>12-14</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>15-17</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage Change in Psoriasis Area and Severity Index (PASI) of the Face Last Observation Carried Forward (LOCF) at End of Treatment</title>
        <description>PASI of the face was to be calculated based on the (sub)investigator's assessment of extent (E), redness (R), thickness (T) and scaliness (S) using the following formula:
0.05 (R+T+S) E
It ranged from 0 to 3.6.</description>
        <time_frame>From baseline (Day 0) to end of treatment (Week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190 Ointment</title>
            <description>LEO 80190: Applied once daily</description>
          </group>
          <group group_id="O2">
            <title>Hydrocortisone 10 mg/g Ointment</title>
            <description>Hydrocortisone: Applied once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change in Psoriasis Area and Severity Index (PASI) of the Face Last Observation Carried Forward (LOCF) at End of Treatment</title>
          <description>PASI of the face was to be calculated based on the (sub)investigator's assessment of extent (E), redness (R), thickness (T) and scaliness (S) using the following formula:
0.05 (R+T+S) E
It ranged from 0 to 3.6.</description>
          <units>percentage of change in PASI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-60.8" spread="51.1"/>
                    <measurement group_id="O2" value="-54.2" spread="59.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>ANOVA</method>
            <method_desc>Treatment comparison using an ANOVA model with age group and treatment as design variables.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.7</ci_lower_limit>
            <ci_upper_limit>31.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment (IGA) of Disease Severity on the Face LOCF</title>
        <description>For subjects with a baseline (Day 0) severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of the face.
For subjects with a baseline (Day 0) severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of the face.
At baseline (Day 0) to end of treatment (Week 8) the (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below.
Clear, almost clear, mild, moderate, severe and very severe.</description>
        <time_frame>At end of treatment (Week 8)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190 Ointment</title>
            <description>LEO 80190: Applied once daily</description>
          </group>
          <group group_id="O2">
            <title>Hydrocortisone 10 mg/g Ointment</title>
            <description>Hydrocortisone: Applied once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment (IGA) of Disease Severity on the Face LOCF</title>
          <description>For subjects with a baseline (Day 0) severity of moderate or worse - &quot;controlled disease&quot; of the face was defined as clear or almost clear according to the IGA of the face.
For subjects with a baseline (Day 0) severity of mild - &quot;controlled disease&quot; of the face was defined as clear according to the IGA of the face.
At baseline (Day 0) to end of treatment (Week 8) the (sub) investigator made an assessment of the disease severity of the face using the 6-category scale below.
Clear, almost clear, mild, moderate, severe and very severe.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Controlled</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-controlled</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change in PASI of the Face LOCF at Week 4</title>
        <description>PASI of the face was to be calculated based on the (sub)investigator's assessment of extent (E), redness (R), thickness (T) and scaliness (S) using the following formula:
0.05 (R+T+S) E It ranged from 0 to 3.6.</description>
        <time_frame>From baseline (Day 0) to Week 4 (Day 28)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190 Ointment</title>
            <description>LEO 80190: Applied once daily</description>
          </group>
          <group group_id="O2">
            <title>Hydrocortisone 10 mg/g Ointment</title>
            <description>Hydrocortisone: Applied once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change in PASI of the Face LOCF at Week 4</title>
          <description>PASI of the face was to be calculated based on the (sub)investigator's assessment of extent (E), redness (R), thickness (T) and scaliness (S) using the following formula:
0.05 (R+T+S) E It ranged from 0 to 3.6.</description>
          <units>percentage of change in PASI</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-54.8" spread="33.8"/>
                    <measurement group_id="O2" value="-54.9" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment (IGA) of Disease Severity of the Intertriginous Areas LOCF</title>
        <description>At baseline (Day 0) to end of treatment (Week 8) the (sub)investigator made an assessment of the disease severity of the intertriginous areas using the following 6-category scale.
Clear, almost clear, mild, moderate, severe and very severe.
For subjects with a baseline (Day 0) severity of moderate or worse - &quot;controlled disease&quot; of the intertriginous areas was defined as clear or almost clear according to the IGA of the intertriginous areas.
For subjects with a baseline (Day 0) severity of mild - &quot;controlled disease&quot; of the intertriginous areas was defined as clear according to the IGA of the intertriginous areas.</description>
        <time_frame>At end of treatment (Week 8)</time_frame>
        <population>The intertriginous analysis set consisted of all participants having ‘Mild’ or worse according to IGA of the intertriginous areas at baseline. The intertriginous analysis set therefore consisted of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190 Ointment</title>
            <description>LEO 80190: Applied once daily</description>
          </group>
          <group group_id="O2">
            <title>Hydrocortisone 10 mg/g Ointment</title>
            <description>Hydrocortisone: Applied once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With &quot;Controlled Disease&quot; According to the Investigator's Global Assessment (IGA) of Disease Severity of the Intertriginous Areas LOCF</title>
          <description>At baseline (Day 0) to end of treatment (Week 8) the (sub)investigator made an assessment of the disease severity of the intertriginous areas using the following 6-category scale.
Clear, almost clear, mild, moderate, severe and very severe.
For subjects with a baseline (Day 0) severity of moderate or worse - &quot;controlled disease&quot; of the intertriginous areas was defined as clear or almost clear according to the IGA of the intertriginous areas.
For subjects with a baseline (Day 0) severity of mild - &quot;controlled disease&quot; of the intertriginous areas was defined as clear according to the IGA of the intertriginous areas.</description>
          <population>The intertriginous analysis set consisted of all participants having ‘Mild’ or worse according to IGA of the intertriginous areas at baseline. The intertriginous analysis set therefore consisted of 11 participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Controlled</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-controlled</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Percentage Change in Total Sign Score (TSS) of the Intertriginous Areas LOCF</title>
        <description>For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the intertriginous areas was determined according to the scale below:
Redness 0.none
mild
moderate
severe
very severe
Thickness
0.none
mild
moderate
severe
very severe
Scaliness
0.none
mild
moderate
severe
very severe A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS ranging from 0 to 12.</description>
        <time_frame>From baseline (Day 0) to end of treatment (Week 8)</time_frame>
        <population>The intertriginous analysis set consisted of all participants having 'Mild' or worse according to IGA of the intertriginous areas at baseline. The intertriginous analysis set therefore consisted of 11 participants.</population>
        <group_list>
          <group group_id="O1">
            <title>LEO 80190 Ointment</title>
            <description>LEO 80190: Applied once daily</description>
          </group>
          <group group_id="O2">
            <title>Hydrocortisone 10 mg/g Ointment</title>
            <description>Hydrocortisone: Applied once daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage Change in Total Sign Score (TSS) of the Intertriginous Areas LOCF</title>
          <description>For each clinical sign, a single score, reflecting the average severity of all psoriatic lesions on the intertriginous areas was determined according to the scale below:
Redness 0.none
mild
moderate
severe
very severe
Thickness
0.none
mild
moderate
severe
very severe
Scaliness
0.none
mild
moderate
severe
very severe A mean score was calculated for each sign (redness, thickness and scaliness) based on scores of all the defined intertriginous areas with psoriasis at baseline and the sum of these mean scores constituted the TSS ranging from 0 to 12.</description>
          <population>The intertriginous analysis set consisted of all participants having 'Mild' or worse according to IGA of the intertriginous areas at baseline. The intertriginous analysis set therefore consisted of 11 participants.</population>
          <units>percentage in TSS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.6" spread="38.2"/>
                    <measurement group_id="O2" value="-93.2" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline (Day 0) to follow-up</time_frame>
      <desc>Follow-up visit only applicable if an AE (serious or non-serious) classified as possibly / probably related to the study medication or not assessable in relation to the study medication was present at the subject’s last on-treatment visit. This follow-up had to be performed 14 ± 2 days after the subject’s last on-treatment visit or until final outcome of the AE was determined, whichever came first.</desc>
      <group_list>
        <group group_id="E1">
          <title>LEO 80190 Ointment</title>
          <description>LEO 80190: Applied once daily</description>
        </group>
        <group group_id="E2">
          <title>Hydrocortisone 10 mg/g Ointment</title>
          <description>Hydrocortisone: Applied once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (6.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site burning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nail dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash scaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Company acknowledges the investigators’ right to publish the entire results of the study, irrespective of outcome. The Company retains the right to have any publication submitted to the Company for review at least 30 days prior to the same paper being submitted for publication or presentation. Investigators must undertake not to submit any part of their individual data for publication without the prior consent of LEO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <phone>+45 4494 5888</phone>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

